BANK OF NOVA SCOTIA - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.

Quarter-by-quarter ownership
BANK OF NOVA SCOTIA ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$1,513,378
-1.2%
42,451
+11.1%
0.00%
-20.0%
Q1 2023$1,531,820
-66.7%
38,200
-61.5%
0.01%
-58.3%
Q4 2022$4,595,936
+11.9%
99,2000.0%0.01%
-7.7%
Q3 2022$4,108,000
+80.0%
99,200
+159.0%
0.01%
+160.0%
Q2 2022$2,282,00038,3030.01%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2022
NameSharesValueWeighting ↓
First Light Asset Management, LLC 213,887$29,608,0002.19%
Rock Springs Capital Management LP 566,500$78,421,0001.66%
FEDERATED HERMES, INC. 4,280,528$592,554,0001.21%
AtonRa Partners 17,646$2,443,0001.20%
EMERALD MUTUAL FUND ADVISERS TRUST 218,390$30,232,0001.05%
EMERALD ADVISERS, LLC 226,875$31,406,0001.04%
Atika Capital Management LLC 89,000$12,319,0000.96%
Capital Impact Advisors, LLC 25,582$3,541,0000.87%
JGP Global Gestao de Recursos Ltda. 1,586$220,0000.83%
CAPITAL INTERNATIONAL LTD /CA/ 79,742$11,039,0000.64%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders